Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
Authors:
Preprint
Abstract
Summary: The SARS-CoV-2 Omicron variant has challenged the control of the COVID-19 pandemic even in highly vaccinated countries. While a second booster of mRNA vaccines improved the immunity against SARS-CoV-2, the humoral and cellular responses induced by a second booster of an inactivated SARS-CoV-2 vaccine have not been studied. In the context of a phase 3 clinical study, we report that a second booster of CoronaVac ® increased the neutralizing response against the ancestral virus yet showed poor neutralization against the Omicron variant. Additionally, isolated PBMCs displayed equivalent activation of specific CD4 + T cells and IFN-γ production when stimulated with a mega-pool of peptides derived from the spike protein of the ancestral virus or the Omicron variant. In conclusion, a second booster dose of CoronaVac ® does not improve the neutralizing response against the Omicron variant compared with the first booster dose, yet it helps maintaining a robust spike-specific CD4 + T cell response.Keywords
This publication has 34 references indexed in Scilit:
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine in ChileNew England Journal of Medicine, 2021
- Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderlyRheumatology International, 2021
- Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in ChileScience Advances, 2021
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infectionScience, 2021
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- An overview of current COVID-19 vaccine platformsComputational and Structural Biotechnology Journal, 2021
- Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infectionScience Immunology, 2020
- Development of an inactivated vaccine candidate for SARS-CoV-2Science, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020